Beckley Psytech To Evaluate Psilocybin In A Rare Debilitating Headache

VC-Backed Biotech To Target SUNHA

The effect of low-dose psilocybin, a compound found in mushrooms, on a rare debilitating condition, short-lasting unilateral neuralgiform headaches attacks, is to be evaluated by the 2019-founded UK biotech, Beckley Psytech.

mushrooms Psilocybe
Psilocybe mushrooms • Source: Alamy

The UK company Beckley Psytech is the latest biotech to raise investor funding to support the evaluation of psychedelic compounds, and in particular the serotonin 5HT2-alpha agonist, psilocybin, as potential therapeutics, a sector that has seen companies marshalling resources to develop their candidates, often with weighty financial backing. 

For example, the Berlin, Germany-based company atai Life Sciences BV raised $258.8m in gross proceeds from an IPO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category